What is CardioDiagnostics?
CardioDiagnostics operates at the intersection of medical technology and digital health, providing a robust suite of FDA-cleared wearable monitoring devices. Their core product ecosystem, which includes the Lifesignals Wearable Biosensor and the Trident Pro, is augmented by the CloudBeat Software platform. This integrated approach allows for real-time data transmission and continuous 24/7 patient monitoring, effectively bridging the gap between clinical diagnostics and remote patient management. By serving a diverse clientele that spans healthcare providers, patients, and OEM manufacturers, the company has established a defensible market position centered on diagnostic precision, data security, and operational efficiency in cardiac care.
How much funding has CardioDiagnostics raised?
CardioDiagnostics has raised a total of $7M across 1 funding round:
Angel/Seed
$7M
Angel/Seed (2015): $7M, investors not publicly disclosed
Key Investors in CardioDiagnostics
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for CardioDiagnostics?
Looking ahead, the infusion of capital is expected to accelerate the deployment of CardioDiagnostics' next-generation monitoring solutions. The company is likely to prioritize the expansion of its CloudBeat Software capabilities, aiming to enhance interoperability with existing hospital information systems. Furthermore, the strategic focus will likely shift toward scaling its technician-led monitoring services to meet the rising demand for remote patient care. As the firm transitions from its initial development phase into a period of rapid commercialization, the emphasis will remain on securing additional clinical partnerships and refining its diagnostic algorithms to maintain a competitive edge in the high-growth wearable health technology sector.
See full CardioDiagnostics company page
